Pyxis Oncology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.9M | $16.1M | — | — | — |
| Cost of revenue | $2.4M | $475,000 | — | — | — |
| Research and development | $73.7M | $58.7M | $49.6M | $86.1M | $51.1M |
| Operating expenses | — | — | $82.2M | $123.5M | $69.7M |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M | -$69.7M |
| Pretax income | -$78.2M | -$79.5M | -$73.8M | — | — |
| Income tax expense | $1.4M | -$2.2M | — | — | — |
| Net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M | -$76.0M |
| Balance Sheet | |||||
| Cash and equivalents | $15.4M | $19.5M | $9.7M | $179.3M | $274.7M |
| Current assets | $72.1M | $132.4M | $124.6M | $186.6M | $278.7M |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M |
| Current liabilities | $21.1M | $17.7M | $25.8M | $31.6M | $18.7M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M |
| Stockholders' equity | $53.4M | $120.8M | $125.7M | $160.8M | $261.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$63.5M | -$57.7M | -$70.7M | -$89.3M | -$35.3M |
| Depreciation and amortization | $4.5M | $3.0M | $1.9M | $709,000 | $647,000 |
| Stock-based compensation | $11.8M | $12.9M | $16.9M | $15.8M | $6.4M |
| Capital expenditure | $9,000 | $237,000 | $6.7M | $6.4M | $540,000 |
| Free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | -$35.9M |
| Impairments | $0 | $21.0M | $0 | — | — |
Shares outstanding 63.4M · Free float 52.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.